Pharma Journalist -

ProBioGen AG and Pionyr Immunotherapeutics announced a second service and license agreement to develop novel antibody therapeutics. Under the terms of the agreement, ProBioGen will…
Read More...

International Stem Cell Corporation, a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, announced that its…
Read More...

BioIVT announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems…
Read More...

Teva Pharmaceutical Industries  announced the launch of a generic version of Uceris1 (budesonide) extended-release tablets, 9 mg, in the U.S. Budesonide extended-release tablets are…
Read More...

Herantis Pharma Plc announced the initiation of a non-invasive CDNF development program to broaden the application of CDNF in Parkinson’s disease and potentially other neurodegenerative…
Read More...

Axovant Sciences announced that it has licensed exclusive global rights to an investigational Silence-and-Replace gene therapy program from Benitec Biopharma for the treatment of…
Read More...

Mylan announced the U.S. launch of Rivastigmine Transdermal System, 4.6 mg/24 hrs, 9.5 mg/24 hrs and 13.3 mg/24 hrs, a generic version of Novartis' Exelon Patch. Mylan received final…
Read More...

MabVax Therapeutics Holdings and Boehringer Ingelheim announced they have signed an asset acquisition and related agreements centered on MabVax's program targeting a glycan commonly…
Read More...

SMi Group reports: Exclusive interviews with Toni Mathieson - Niemann-Pick UK and Nicolas Sireau - AKU Society in the run up to the Orphan Drugs and Rare Diseases Conference taking…
Read More...

TRIGR Therapeutics, a US-based Biopharmaceutical company, and ABL Bio Corporation, a South Korean biotechnology company, jointly announced that it had entered into a binding agreement…
Read More...